NO974726L - Glucose-induktibel, rekombinant, viral vektor - Google Patents

Glucose-induktibel, rekombinant, viral vektor

Info

Publication number
NO974726L
NO974726L NO974726A NO974726A NO974726L NO 974726 L NO974726 L NO 974726L NO 974726 A NO974726 A NO 974726A NO 974726 A NO974726 A NO 974726A NO 974726 L NO974726 L NO 974726L
Authority
NO
Norway
Prior art keywords
inducible
recombinant
glucose
viral vector
viral
Prior art date
Application number
NO974726A
Other languages
English (en)
Norwegian (no)
Other versions
NO974726D0 (no
Inventor
Ruihuan Chen
Bruno Doiron
Axel Kahn
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of NO974726L publication Critical patent/NO974726L/no
Publication of NO974726D0 publication Critical patent/NO974726D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO974726A 1995-04-14 1997-10-13 Glucose-induktibel, rekombinant, viral vektor NO974726D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504558A FR2732978B1 (fr) 1995-04-14 1995-04-14 Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
PCT/FR1996/000560 WO1996032489A1 (fr) 1995-04-14 1996-04-12 Vecteur viral recombinant inductible par le glucose

Publications (2)

Publication Number Publication Date
NO974726L true NO974726L (no) 1997-10-13
NO974726D0 NO974726D0 (no) 1997-10-13

Family

ID=9478162

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974726A NO974726D0 (no) 1995-04-14 1997-10-13 Glucose-induktibel, rekombinant, viral vektor

Country Status (14)

Country Link
US (1) US6309878B1 (pt)
EP (1) EP0821741A1 (pt)
JP (1) JPH11503608A (pt)
KR (1) KR19980703843A (pt)
AU (1) AU715377B2 (pt)
BR (1) BR9604938A (pt)
CA (1) CA2215987A1 (pt)
CZ (1) CZ292564B6 (pt)
FR (1) FR2732978B1 (pt)
HU (1) HUP9802587A3 (pt)
MX (1) MX9707910A (pt)
NO (1) NO974726D0 (pt)
SK (1) SK137797A3 (pt)
WO (1) WO1996032489A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021363A1 (en) * 1996-11-15 1998-05-22 Millennium Pharmaceuticals, Inc. Compositions and methods for treating type ii diabetes involving hnf-4
US6537806B1 (en) 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
EP1153131B1 (en) 1999-02-19 2007-09-26 enGene, Inc. Compositions for gene therapy of diabetes
JP3406244B2 (ja) * 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
JP3581346B2 (ja) 1999-05-27 2004-10-27 ヒタチグローバルストレージテクノロジーズネザーランドビーブイ ディスク装置
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
DE102005024884A1 (de) * 2005-05-31 2006-12-07 Linde Ag Arbeitsmaschine, insbesondere Flurförderzeug
CN101212977A (zh) * 2005-06-01 2008-07-02 国际创新生物技术研究所有限公司 葡萄糖可诱导的胰岛素表达和治疗糖尿病的方法
ES2325711B1 (es) * 2007-04-17 2010-06-17 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (Ciemat) Vectores de expresion que comprenden el promotor del gen pklr humano y su uso para la elaboracion de composiciones farmaceuticas destinadas a terapia genica somatica con expresion especifica en celulas eritroides.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109579A1 (en) * 1991-05-29 1992-12-10 Julianna Lisziewicz Eukaryotic expression vectors with regulation of rna processing
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
AU687836B2 (en) * 1993-06-28 1998-03-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose

Also Published As

Publication number Publication date
WO1996032489A1 (fr) 1996-10-17
EP0821741A1 (fr) 1998-02-04
BR9604938A (pt) 1998-06-09
JPH11503608A (ja) 1999-03-30
CZ325197A3 (cs) 1998-01-14
NO974726D0 (no) 1997-10-13
US6309878B1 (en) 2001-10-30
MX9707910A (es) 1997-11-29
FR2732978B1 (fr) 1997-05-30
KR19980703843A (ko) 1998-12-05
AU5652396A (en) 1996-10-30
SK137797A3 (en) 1998-05-06
HUP9802587A3 (en) 1999-12-28
HUP9802587A2 (hu) 1999-02-01
CA2215987A1 (fr) 1996-10-17
AU715377B2 (en) 2000-02-03
FR2732978A1 (fr) 1996-10-18
CZ292564B6 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
AU2678097A (en) Targeted viral vectors
AU5638496A (en) Viral vectors
HUP9802217A3 (en) Recombinant mva virus, and the use thereof
NO2010013I1 (no) Rekombinant FSH-CTP
AU3119895A (en) Recombinant virus vectors
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
DE69420033D1 (de) Gibbon leukemia virus retrovirale vektoren
NO974562D0 (no) Antifugale, cykliske peptider
DE69926557D1 (de) Reduziertes Vektor Raster
HUP9801266A3 (en) Multimeric, recombinant urease vaccine
NO976058L (no) Rekombinant mistellectin
TR199500915A2 (tr) Peptidler.
NO974726D0 (no) Glucose-induktibel, rekombinant, viral vektor
ATE348169T1 (de) Selektiv-replizierende virale vectoren
AU2344100A (en) Viral vectors with late transgene expression
FI933980A0 (fi) Skyddsplagg foer hygienkraevande objekt, saosom operationssalar
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
SG60187A1 (en) Transgenic virus
FR2736358B1 (fr) Virus myxomateux recombinant
FI973245A (fi) Verisuonia supistavat substituoidut 2,3-dihydro-1,4-dioksinopyridiinit
BR9605220B1 (pt) gonadotropinas recombinantes.
GB9811171D0 (en) Viral vector
GB9702990D0 (en) Virus vaccine
ES1032571Y (es) Gafa,
GB9501300D0 (en) Peptides which inhibit viruses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application